Urinary p-cresol is elevated in young French children with autism spectrum disorder: A replication study

Biomarkers

Volumn 19, Issue 6, 2014, Pages 463-470

  Gabriele, Stefano ^a   Sacco, Roberto ^a   Cerullo, Sonia ^a,h   Neri, Cristina ^b,c   Urbani, Andrea ^b,c   Tripi, Gabriele ^d,e   Malvy, Joëlle ^f   Barthelemy, Catherine ^f   Bonnet Brihault, Frédérique ^f   Persico, Antonio M ^a,g  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e Childhood Psychiatric Service for Neurodevelopmentals Disorders   (France)

^f Université de Tours   (France)

^g Mafalda Luce Center for Pervasive Developmental Disorders   (Italy)

^h DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

Gut flora; Neurotoxicity; Organic contaminants; p cresylsulfate; Pervasive developmental disorders

Indexed keywords

PARA CRESOL; PARA CRESYLGLUCURONATE; PARA CRESYLSULFATE; UNCLASSIFIED DRUG; 4-CRESOL; 4-CRESOL SULFATE; CRESOL; GLUCURONIC ACID; SULFATE;

ARTICLE; AUTISM; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPULSION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; REPLICATION STUDY; URINE LEVEL; ADOLESCENT; CASE CONTROL STUDY; FRANCE; PRESCHOOL CHILD; URINE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CRESOLS; FEMALE; FRANCE; GLUCURONATES; HUMANS; MALE; SULFURIC ACID ESTERS;

EID: 84906343033     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.936911     Document Type: Article

References (57)

1. Adrien JL, Roux S, Couturier G, et al. (2001). Towards a new functional assessment of autistic dysfunction in children with developmental disorders: the Behaviour Function Inventory. Autism 5:249-64.
2. Alberti A, Pirrone P, Elia M, et al. (1999). Sulphation deficit in "lowfunctioning" autistic children: a pilot study. Biol Psychiatry 46: 420-4.
3. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, et al. (2010). Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 1801:1175-83.
4. Altieri L, Neri C, Sacco R, et al. (2011). Urinary p-cresol is elevated in small children with severe autism spectrum disorder. Biomarkers 16: 252-60.
5. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing.
6. Ashwood P, Wills S, Van de Water J. (2006). The immune response in autism: a new frontier for autism research. J Leukoc Biol 80:1-15.
7. Barthélémy C, Roux S, Adrien JL, et al. (1997). Validation of the revised behavior summarized evaluation scale. J Autism Dev Disord 27: 139-53.
8. Bergé-Lefranc D, Chaspoul F, Calaf R, et al. (2010). Binding of pcresylsulfate and p-cresol to human serum albumin studied by microcalorimetry. J Phys Chem B 114:1661-5.
9. Bone E, Tamm A, Hill M. (1976). The production of urinary phenols by gut bacteria and their possible role in the causation of large bowler cancer. Am J Clin Nutr 29:1448-54.
10. Bourreau Y, Roux S, Gomot M, et al. (2009). Validation of the repetitive and restricted behaviour scale in autism spectrum disorders. Eur Child Adolesc Psychiatry 18:675-82.
11. Brunet O, Lézin I. (1976). Le développement psychologique de la première enfance, 5e éd Issy-les-Moulineaux, Editions scientifiques et psychologiques.
12. Cafaro V, Notomista E, Capasso P, Di Donato A. (2005). Mutation of glutamic acid 103 of toluene o-xylene monooxygenase as a means to control the catabolic efficiency of a recombinant upper pathway for degradation of methylated aromatic compounds. Appl Environ Microbiol 71:4744-50.
13. Chiu CA, Lu LF, Yu TH, et al. (2010). Increased levels of total P-cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud 7:275-84.
14. De Angelis M, Piccolo M, Vannini L, et al. (2013). Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One 8:e76993.
15. De Bruin A. (1976). Metabolism of occupational agents. In: De Bruin A, ed. Biochemical toxicology of environmental agents. Amsterdam: Elsevier/North-Holland Biomedical Press, 87-170.
16. De Magistris L, Familiari V, Pascotto A, et al. (2010). Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 51:418-24.
17. De Smet R, Van Kaer J, Van Vlem B, et al. (2003) Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 49: 470-8.
18. DEufemia P, Celli M, Finocchiaro R, et al. (1996). Abnormal intestinal permeability in children with autism. Acta Paediatr 85:1076-9.
19. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). (2014). Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 63:1-21.
20. de Wouters T, Doré J, Lepage P. (2012). Does our food (environment) change our gut microbiome (in-vironment): a potential role for inflammatory bowel disease? Dig Dis 30:33-9
21. Emond P, Mavel S, Aïdoud N, et al. (2013). GC-MS-based urine metabolic profiling of autism spectrum disorders. Anal Bioanal Chem 405:5291-300.
22. Finegold SM, Molitoris D, Song Y, et al. (2002). Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 35:6-16.
23. Griffiths R. (1970). The abilities of young children. London: Child Development Center.
24. Holmes E, Loo RL, Stamler J, et al. (2008). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453: 396-400.
25. Hsiao EY, McBride SW, Hsien S, et al. (2013). Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155:1451-63.
26. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. (2005). Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 51:77-85.
27. Jyonouchi H, Geng L, Streck DL, Toruner GA. (2011). Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol 238: 73-80.
28. Kȩsli R, Gökȩen C, Buluǧ U, Terzi Y. (2014). Investigation of the relation between anaerobic bacteria genus clostridium and late-onset autism etiology in children. J Immunoassay Immunochem 35:101-9.
29. Leblond CS, Heinrich J, Delorme R, et al. (2012). Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet 8:e1002521.
30. Liabeuf S, Barreto DV, Barreto FC, et al. (2010). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25:1183-91.
31. Lord C, Rutter M, DiLavore PC, Risi S. (2002). ADOS, Autism Diagnostic Observation Schedule. Los Angeles (CA): Western Psychological Services [Italian version by Tancredi R, Saccani M, Persico AM, Parrini B, Igliozzi R, Faggioli R, eds. (2005). Florence, Italy: Organizzazioni Speciali].
32. MacFabe DF, Cain NE, Boon F, et al. (2011). Effects of the entericbacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: relevance to autism spectrum disorder. Behav Brain Res 217:47-54.
33. Mandel HG. (1971). Pathways of drug biotransformation: biochemical conjugations. In: LaDu BN, Mandel HG, Way EL, eds. Pathways of drug biotransformation. Baltimore (MD): Williams and Wilkins, 149-86.
34. Mavel S, Nadal-Desbarats L, Blasco H, et al. (2013). 1H-13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta 114:95-102.
35. Meert N, Schepers E, Glorieux G, et al. (2012). Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol Dial Transplant 27:2388-96.
36. Meijers BK, Bammens B, De Moor B, et al. (2008). Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73:1174-80.
37. Neri C, Gabriele S, Bernardini S, et al. Urine metabolic profiling of autistic children: insight into microbial metabolic impact. Unpublished manuscript. OECD. (2003). m-/p-Cresol Category, Screening Information Data Set, Initial Assessment Report. Paris: UNEP Publications. Available from: www.chem.unep.ch/irptc/sids/oecdsids/m-pcresols.pdf.
38. Pascucci T, Persico AM. Effects of acute p-cresol administration in rodent models of human ASD. Unpublished manuscript. Perron-Borrel. (1996). EDEI-R, échelles differentielles defficience intellecuelle-forme révisée. Paris, Editions du Centre de psychologique appliquée. Persico AM, Merelli S. (in press). Key issues in mental health. Vol. 179/ Chapter 10.
39. Persico AM, Napolioni V. (2012). Urinary p-cresol in autism spectrum disorder. Neurotoxicol Teratol 36:82-90.
40. Persico AM, Napolioni V. (2013). Autism genetics. Behav Brain Res 251:95-112.
41. Ramakrishna BS, Roberts-Thomson IC, Pannall PR, Roediger WE. (1991). Impaired sulphation of phenol by the colonic mucosa in quiescent and active ulcerative colitis. Gut 32:46-9.
42. Renwick AG, Thakrar A, Lawrie CA, George CF. (1988). Microbial amino acid metabolites and bladder cancer: no evidence of promoting activity in man. Hum Toxicol 7:267-72.
43. Robertson MA, Sigalet DL, Holst JJ, et al. (2008). Intestinal permeability and glucagon-like peptide-2 in children with autism: a controlled pilot study. J Autism Dev Disord 38:1066-71.
44. Ruggeri B, Sarkans U, Schumann G, Persico AM. (2014). Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl) 231:1201-16.
45. Rutter M, Le Couter A, Lord C. (2003). ADI-R, autism diagnostic interview-revised. Los Angeles (CA): Western Psychological Services [Italian version by Faggioli R, Saccani M, Persico AM, Tancredi R, Parrini B, Igliozzi R, eds. (2005). Florence, Italy: Organizzazioni Speciali].
46. Sacco R, Curatolo P, Manzi B, et al. (2010). Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Res 3:237-52.
47. Schepers E, Meert N, Glorieux G, et al. (2007). p-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22:592-6.
48. Schopler E, Reichler RJ, Rochen Renner BR. (1986). The Childhood Autism Rating Scale for diagnostic screening and classification of autism. New York (NY): Irvington.
49. Selmer T, Andrei PI. (2001). p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of p-cresol. Eur J Biochem 268:1363-72.
50. Walsh P, Elsabbagh M, Bolton P, Singh I. (2011). In search of biomarkers for autism: scientific, social and ethical challenges. Nat Rev Neurosci 12:603-12.
51. Wang CP, Lu LF, Yu TH, et al. (2010). Serum levels of total pcresylsulphate are associated with angiographic coronary atherosclerosis severity instable angina patients with early stage of renal failure. Atherosclerosis 211:579-83.
52. Wang CP, Lu LF, Yu TH, et al. (2013). Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. J Nephrol 26:111-18.
53. Wang Y, Kasper LH. (2014). The role of microbiome in central nervous system disorders. Brain Behav Immun 38:1-12.
54. Wang L, Christophersen CT, Sorich MJ, et al. (2011). Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. Appl Environ Microbiol 77:6718-21.
55. Wechsler D. (2005). WISC-IV, échelle dintelligence de Wechsler pour enfants, 4e ed. Paris: Editions du Centre de psychologie appliquée.
56. Whiteley P, Waring R, Williams L, et al. (2006). Spot urinary creatinine excretion in pervasive developmental disorders. Pediatr Int 48:292-7.
57. Yap IK, Angley M, Veselkov KA, et al. (2010). Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 9:2996-3004.